Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine
about
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesBroadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early timeDevelopment of universal influenza vaccines based on influenza virus M and NP genes.A highly immunogenic vaccine against A/H7N9 influenza virusVaccine development for protecting swine against influenza virus.Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature developmentProtective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 HexonAn adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models.Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice.Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Pre-existing immunity against vaccine vectors--friend or foe?Recombinant influenza vaccines.Nasal and pulmonary vaccine delivery using particulate carriers.Vaccines for the prevention against the threat of MERS-CoV.Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.A highly sensitive europium nanoparticle-based immunoassay for detection of influenza A/B virus antigen in clinical specimensIRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.Evaluating the promise of recombinant transmissible vaccines.A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose
P2860
Q27013568-23ADD2A0-A278-4FAA-A043-0C87CCB36FFBQ30223058-76AE8A21-F0A8-446C-B928-6F7B8FB05191Q30353770-1CB277BE-0283-4714-B8A9-CE92FF162471Q30355116-494C2BD3-CFE0-44F8-9D61-C020C506B3B2Q30383516-5C41B6FB-1533-4B0A-9ABB-3CCE7F7A1AD5Q30424943-B8D6028B-6164-4C07-8F39-1CCBC35EE0D3Q30434991-9D0CB027-3A95-4975-8D9C-17B460E4AF79Q35656657-9E723719-AC92-4063-B5DF-243DA7D1FCB6Q35871976-4E89A18C-A2B9-4183-A212-9FD60C57FD25Q35887739-D4E4883E-C268-4011-B1F7-0AB1CD7F5566Q36058021-1BADDC17-DFFB-456F-9C7D-B37DAFAEA2D0Q36504789-F7FA9399-4D5D-458A-827D-7DD2E0BE3EEFQ36625165-C71ED5EF-E838-4F47-AD25-C7D825626D6AQ37331004-8D197A39-F390-43E4-9AA1-1339652ACAAEQ37627897-3034DE3E-A56B-4238-B7BF-2AB9640D9E14Q38061876-4FCDE864-1E99-4130-8624-BF3A2A039736Q38076422-30978914-B575-418C-85E3-C956224E5834Q38465267-6E106CC4-B3C8-4434-B71D-534E635E9978Q38778044-E3673B90-F583-411E-9348-E183ECF8A0BFQ41918215-5603685A-7C1E-4193-8B64-C51C002C193FQ42184039-47581BD7-DDDE-4EA5-8D53-F5F881868808Q47262061-7B3CA446-3B9C-474B-9355-1D77D267BAB5Q47571361-EF3706E9-4A5C-412A-8570-CF0E8F464DE1Q56901675-59045107-3089-4EF8-9FDB-5EA899063834
P2860
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@ast
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en-gb
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@nl
type
label
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@ast
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en-gb
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@nl
altLabel
Impact of Preexisting Adenovir ...... s-Based H5N1 Influenza Vaccine
@en
prefLabel
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@ast
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en-gb
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@nl
P2093
P2860
P3181
P1433
P1476
Impact of preexisting adenovir ...... s-based H5N1 influenza vaccine
@en
P2093
Aseem Pandey
Laurent Couëtil
Neetu Singh
Sai V Vemula
Suresh K Mittal
Suryaprakash Sambhara
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0033428
P407
P577
2012-01-01T00:00:00Z